Ibnsina Pharma (ISPH) has signed an agreement with the German BoehringerIngelheim to distribute the latter’s treatments across cardiovascular, cardio-renal-metabolic, and respiratory therapeutic areas in Egypt, according to a press release.
“BoehringerIngelheim’s partnership with Ibnsina will further strengthen our leadership position in Egypt and highlights our commitment towards delivering sustainable solutions and treatments to our patients,” Marianne AbouElkheir, General Manager and Head of Human Pharma at BoehringerIngelheim, LINEA, and SSA, said.
Mohsen Mahgoub, Managing Director of Ibnsina Pharma, commented: “With this agreement, our hope is to serve Egypt’s population with BoehringerIngelheim key biopharmaceutical innovations covering important disease areas which include type 2 diabetes, hypertension, and respiratory diseases as well as stroke.”
Ibnsina Pharma is the second-largest pharmaceutical distributor in Egypt, distributing products from over 350 global and local companies to more than 46,000 customers of pharmacies, hospitals, wholesalers, and healthcare institutions.
